National Health Act 1953 - Amendment determination under subsection 85AB(1) - drugs on F1 (No. PB 20 of 2008)

Overview

The Amendment Determination—drugs on F1 (PB 20 of 2008) is a legislative instrument made under subsection 85AB(1) of the National Health Act 1953. This amendment was enacted to refine the list of drugs that are considered to be on the First Schedule (F1) of the Poisons Standard, which regulates the availability and use of scheduled medicines in Australia. By adding Metoprolol succinate to the list, the determination aims to align the legislative framework with contemporary medical practices and ensure that the control of certain substances is appropriately managed. The instrument was prepared by the Office of Legislative Drafting and Publishing, Attorney-General’s Department, and it commenced on 1 February 2008. This legislative action underscores the ongoing commitment to review and update the regulatory environment to meet public health needs and ensure the safe use of medicines.

Scope and Application

The Amendment Determination – drugs on F1 (PB 20 of 2008) as amended, made under subsection 85AB(1) of the National Health Act 1953, applies to the listing of certain drugs on the Commonwealth Register of Therapeutic Goods (RTG). This legislative instrument specifically amends the previous determination (PB 87 of 2007) to include the drug Metoprolol succinate on the F1 list, which pertains to the First Schedule of the Poisons Standard. This amendment is part of the broader regulatory framework for therapeutic goods within Australia, overseen by the Therapeutic Goods Administration (TGA). The geographic reach of this Act is national, applying across all states and territories of Australia, as it falls under Commonwealth legislation. The Act does not explicitly state exclusions or exemptions, but it is understood that its application is contingent on the classification and listing of drugs on the RTG, which are subject to specific criteria under the Poisons Standard. The application of this Act may be further extended or restricted through subordinate instruments issued under the National Health Act 1953.

Key Provisions

The Amendment Determination – drugs on F1 (PB 20 of 2008) amends the Pharmaceutical Benefits Scheme (PBS) to include the drug "Metoprolol succinate" on the PBS formulary (Schedule 1). This legislative instrument, which was registered on 15 January 2008 and commenced on 1 February 2008, is made under subsection 85AB(1) of the National Health Act 1953. The amendment is straightforward: it adds "Metoprolol succinate" to the list of drugs that are on F1, following the entry for "Bortezomib". The obligations and requirements imposed by this amendment are primarily administrative. Pharmaceutical companies that manufacture or supply "Metoprolol succinate" will need to comply with the PBS requirements, which may include registering the drug with the Therapeutic Goods Administration (TGA) and adhering to the pricing and rebate arrangements set out in the PBS. Healthcare providers and pharmacists will also need to be aware of the inclusion of this drug in the PBS, ensuring it is prescribed and dispensed in accordance with PBS guidelines. There are no explicit offences or penalties outlined in the Amendment Determination itself. However, breaches of the PBS regulations, including non-compliance with the inclusion of "Metoprolol succinate", could lead to civil or criminal penalties under the National Health Act 1953. For instance, knowingly supplying a drug that is not eligible for PBS subsidy could result in significant fines. The maximum penalty for contravening provisions of the National Health Act 1953 can be substantial, often reaching up to $222,000 for corporate entities, depending on the specific offence and jurisdiction. This amendment is part of a broader regulatory framework designed to manage the costs and availability of essential medications within Australia. It ensures that "Metoprolol succinate" is accessible to patients through the PBS, contributing to the overall objective of providing affordable and equitable healthcare services. By including this drug on the formulary, the government aims to improve patient access to necessary treatments while maintaining the financial sustainability of the PBS.